CN1582160A - 用于治疗癌的新草本化学组合物 - Google Patents
用于治疗癌的新草本化学组合物 Download PDFInfo
- Publication number
- CN1582160A CN1582160A CNA018239242A CN01823924A CN1582160A CN 1582160 A CN1582160 A CN 1582160A CN A018239242 A CNA018239242 A CN A018239242A CN 01823924 A CN01823924 A CN 01823924A CN 1582160 A CN1582160 A CN 1582160A
- Authority
- CN
- China
- Prior art keywords
- compositions
- cell
- cancer cell
- lignanoid
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 210
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 30
- 201000011510 cancer Diseases 0.000 title claims abstract description 26
- 239000000126 substance Substances 0.000 title description 4
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 51
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 47
- 230000012010 growth Effects 0.000 claims abstract description 47
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 46
- 206010029260 Neuroblastoma Diseases 0.000 claims abstract description 32
- 241000218645 Cedrus Species 0.000 claims abstract description 27
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 22
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 22
- 239000000463 material Substances 0.000 claims abstract description 21
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 14
- 230000001093 anti-cancer Effects 0.000 claims abstract description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 10
- 201000007270 liver cancer Diseases 0.000 claims abstract description 7
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 7
- 201000005202 lung cancer Diseases 0.000 claims abstract description 7
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 7
- 239000000419 plant extract Substances 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 194
- 238000000034 method Methods 0.000 claims description 73
- 206010006187 Breast cancer Diseases 0.000 claims description 45
- 208000026310 Breast neoplasm Diseases 0.000 claims description 45
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 45
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 45
- 201000010881 cervical cancer Diseases 0.000 claims description 45
- 230000010261 cell growth Effects 0.000 claims description 31
- 230000005764 inhibitory process Effects 0.000 claims description 31
- 201000009030 Carcinoma Diseases 0.000 claims description 28
- 201000008275 breast carcinoma Diseases 0.000 claims description 21
- 201000005296 lung carcinoma Diseases 0.000 claims description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 20
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 18
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 claims description 15
- 150000002373 hemiacetals Chemical class 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 13
- 239000011230 binding agent Substances 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 239000000654 additive Substances 0.000 claims description 12
- 230000000996 additive effect Effects 0.000 claims description 12
- 230000037396 body weight Effects 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 12
- 239000000314 lubricant Substances 0.000 claims description 12
- 210000003757 neuroblast Anatomy 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 239000003381 stabilizer Substances 0.000 claims description 12
- 238000007910 systemic administration Methods 0.000 claims description 12
- 241000196324 Embryophyta Species 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 201000001514 prostate carcinoma Diseases 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000003463 adsorbent Substances 0.000 claims description 4
- -1 carrier Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical group ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 241000218646 Cedrus deodara Species 0.000 claims description 2
- 230000005907 cancer growth Effects 0.000 claims description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 210000002149 gonad Anatomy 0.000 claims description 2
- 239000003791 organic solvent mixture Substances 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 abstract description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 abstract description 4
- 210000001072 colon Anatomy 0.000 abstract description 4
- 210000000481 breast Anatomy 0.000 abstract description 3
- 210000000214 mouth Anatomy 0.000 abstract 3
- MATGKVZWFZHCLI-LSDHHAIUSA-N (-)-matairesinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(OC)C(O)=CC=2)=C1 MATGKVZWFZHCLI-LSDHHAIUSA-N 0.000 abstract 2
- 210000003679 cervix uteri Anatomy 0.000 abstract 2
- 229930013686 lignan Natural products 0.000 abstract 2
- 150000005692 lignans Chemical group 0.000 abstract 2
- 235000009408 lignans Nutrition 0.000 abstract 2
- 210000004185 liver Anatomy 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 210000001672 ovary Anatomy 0.000 abstract 2
- 230000002195 synergetic effect Effects 0.000 abstract 2
- ZITBJWXLODLDRH-XOBRGWDASA-N (-)-Nortrachelogenin Natural products C1=C(O)C(OC)=CC(C[C@@H]2[C@@](C(=O)OC2)(O)CC=2C=C(OC)C(O)=CC=2)=C1 ZITBJWXLODLDRH-XOBRGWDASA-N 0.000 abstract 1
- ZITBJWXLODLDRH-UHFFFAOYSA-N (-)-wikstromol Chemical compound C1=C(O)C(OC)=CC(CC2C(C(=O)OC2)(O)CC=2C=C(OC)C(O)=CC=2)=C1 ZITBJWXLODLDRH-UHFFFAOYSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 15
- 230000003013 cytotoxicity Effects 0.000 description 13
- 231100000135 cytotoxicity Toxicity 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 239000002023 wood Substances 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000002026 chloroform extract Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 241000565365 Abies pinsapo Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000766096 Halorubrum sodomense Archaerhodopsin-3 Proteins 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 244000060545 Wikstroemia viridiflora Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229930182783 neolignan Natural products 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940041022 streptomycins Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
生长抑制百分率 | |||||||
(-)-罗汉松脂素(μg/ml) | (-)-南荛酚(μg/ml) | ||||||
10 | 30 | 100 | 10 | 30 | 100 | ||
乳腺癌 | MCF-7 | 10 | 36 | 54 | 7 | 26 | 51 |
乳腺癌 | ZR-75-1 | 62 | 37 | ||||
成神经细胞瘤 | SKNMC | 75 | 44 | ||||
成神经细胞瘤 | IMR-32 | 77 | 56 | ||||
子宫颈癌 | SiHa | 10 | 29 | 63 | 16 | 21 | 37 |
结肠癌 | Colo-205 | 15 | 28 | 93 | 5 | 27 | 67 |
结肠癌 | HT-29 | 10 | 74 | 6 | 32 | ||
结肠癌 | SW-620 | 11 | 68 | 14 | 20 | 50 | |
肝癌 | Hep-2 | 64 | 46 | ||||
肺癌 | A-549 | 19 | 33 | 65 | 21 | 37 | 56 |
HPLC分析的相对百分率 | ||||
(-)-罗汉松脂素 | (-)-南荛酚 | 二苄基丁内半缩醛 | 未确认物质 | |
混合物1 | 12.20 | 77.30 | 7.70 | 2.80 |
混合物2 | 10.50 | 76.30 | 10.27 | 3.00 |
混合物3 | 10.90 | 78.20 | 8.30 | 2.60 |
组织 | 细胞系 | 生长抑制百分率 | ||||||||
混合物1(μg/ml) | 混合物2(μg/ml) | 混合物3(μg/ml) | ||||||||
10 | 30 | 100 | 10 | 30 | 100 | 10 | 30 | 100 | ||
乳腺癌 | MCF-7 | 39 | 63 | 72 | 53 | 63 | 66 | 38 | 65 | 71 |
乳腺癌 | T-47-D | 43 | 71 | 80 | 57 | 76 | 77 | 43 | 70 | 75 |
子宫颈癌 | Hela | 11 | 64 | 65 | 23 | 69 | 69 | 20 | 71 | 73 |
子宫颈癌 | SiHa | 38 | 69 | 89 | 67 | 85 | 88 | 44 | 70 | 89 |
成神经细胞瘤 | SF-539 | 23 | 72 | 81 | 37 | 76 | 83 | 10 | 71 | 84 |
成神经细胞瘤 | SKNMC | 71 | 90 | 91 | 83 | 90 | 90 | 77 | 90 | 92 |
成神经细胞瘤 | IMR-32 | - | - | 86 | - | - | 96 | - | - | 89 |
成神经细胞瘤 | SKNSH | 9 | 62 | 78 | 10 | 65 | 79 | 14 | 72 | 87 |
成神经细胞瘤 | SNB-78 | 26 | 58 | 70 | 46 | 59 | 80 | 28 | 54 | 70 |
结肠癌 | COLO-205 | 40 | 85 | 95 | 83 | 94 | 98 | 38 | 85 | 94 |
结肠癌 | HCT-15 | 24 | 73 | 89 | 45 | 89 | 93 | 21 | 75 | 97 |
结肠癌 | HT-29 | 33 | 76 | 88 | 75 | 85 | 93 | 21 | 78 | 93 |
结肠癌 | SW-620 | 12 | 54 | 89 | 8 | 62 | 89 | 14 | 62 | 95 |
肝癌 | Hep-2 | - | - | 70 | - | - | 73 | - | - | 71 |
肝癌 | Hep-G-2 | 14 | 18 | 37 | 11 | 23 | 51 | 19 | 23 | 59 |
肺癌 | A-549 | 31 | 63 | 83 | 37 | 80 | 82 | 32 | 67 | 83 |
肺癌 | HOP-18 | 2 | 18 | 47 | 9 | 51 | 65 | 0 | 21 | 44 |
肺癌 | NCI-H23 | 35 | 88 | 76 | 57 | 72 | 95 | 28 | 74 | 92 |
口癌 | KB | 41 | 87 | 100 | 43 | 87 | 99 | 51 | 85 | 99 |
卵巢癌 | NIH-OVCAR-3 | 6 | 38 | 44 | 36 | 42 | 48 | 13 | 42 | 37 |
卵巢癌 | OVCAR-5 | 7 | 44 | 83 | 14 | 76 | 93 | 5 | 50 | 96 |
卵巢癌 | SK-OV-3 | 6 | 48 | 70 | 17 | 64 | 83 | 2 | 51 | 79 |
前列腺癌 | DU-145 | 9 | 63 | 81 | 17 | 73 | 81 | 7 | 69 | 82 |
前列腺癌 | PC-3 | 45 | 91 | 93 | 77 | 92 | 96 | 53 | 94 | 98 |
Claims (93)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2001/000214 WO2003047608A1 (en) | 2001-12-05 | 2001-12-05 | A novel herbal chemical composition for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1582160A true CN1582160A (zh) | 2005-02-16 |
CN100444837C CN100444837C (zh) | 2008-12-24 |
Family
ID=11076415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018239242A Expired - Fee Related CN100444837C (zh) | 2001-12-05 | 2001-12-05 | 用于治疗癌的新草本化学组合物 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1465645A1 (zh) |
JP (1) | JP2005511659A (zh) |
KR (1) | KR20040072646A (zh) |
CN (1) | CN100444837C (zh) |
AU (1) | AU2002222501A1 (zh) |
CA (1) | CA2469093A1 (zh) |
WO (1) | WO2003047608A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104523721A (zh) * | 2014-11-11 | 2015-04-22 | 济南星懿医药技术有限公司 | 一种抗肿瘤的药物组合物 |
CN113633704A (zh) * | 2021-08-23 | 2021-11-12 | 中山大学 | 一种细轴荛花叶提取物的制备方法及其应用 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20106293A0 (fi) | 2010-12-06 | 2010-12-06 | Emilia Peuhu | Uudet farmaseuttiset koostumukset |
KR101416505B1 (ko) * | 2012-03-15 | 2014-07-09 | 연세대학교 산학협력단 | 마타이레시놀을 포함하는 혈관신생 억제용 약제학적 조성물 |
CN109206394B (zh) * | 2018-08-16 | 2022-04-01 | 广西壮族自治区中国科学院广西植物研究所 | 一种倍半木脂素化合物、其制备方法及应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6261565B1 (en) * | 1996-03-13 | 2001-07-17 | Archer Daniels Midland Company | Method of preparing and using isoflavones |
-
2001
- 2001-12-05 JP JP2003548863A patent/JP2005511659A/ja active Pending
- 2001-12-05 EP EP01274887A patent/EP1465645A1/en not_active Withdrawn
- 2001-12-05 KR KR10-2004-7008727A patent/KR20040072646A/ko not_active Application Discontinuation
- 2001-12-05 WO PCT/IN2001/000214 patent/WO2003047608A1/en active Application Filing
- 2001-12-05 CN CNB018239242A patent/CN100444837C/zh not_active Expired - Fee Related
- 2001-12-05 CA CA002469093A patent/CA2469093A1/en not_active Abandoned
- 2001-12-05 AU AU2002222501A patent/AU2002222501A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104523721A (zh) * | 2014-11-11 | 2015-04-22 | 济南星懿医药技术有限公司 | 一种抗肿瘤的药物组合物 |
CN113633704A (zh) * | 2021-08-23 | 2021-11-12 | 中山大学 | 一种细轴荛花叶提取物的制备方法及其应用 |
CN113633704B (zh) * | 2021-08-23 | 2022-06-07 | 中山大学 | 一种细轴荛花叶提取物的制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100444837C (zh) | 2008-12-24 |
EP1465645A1 (en) | 2004-10-13 |
JP2005511659A (ja) | 2005-04-28 |
KR20040072646A (ko) | 2004-08-18 |
AU2002222501A1 (en) | 2003-06-17 |
WO2003047608A1 (en) | 2003-06-12 |
CA2469093A1 (en) | 2003-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1154488C (zh) | 免疫抑制剂 | |
CN1131237C (zh) | 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙 | |
CN1990484A (zh) | 水飞蓟宾酯类衍生物及其制备方法和用途 | |
CN1303388A (zh) | 铂配合物、其制备和治疗应用 | |
CN1708312A (zh) | 新的天然来源的葡萄糖苷酶抑制剂 | |
CN1807404A (zh) | 一类白藜芦醇的衍生物及其制法和用途 | |
CN1050021A (zh) | 二萜内酯化合物的合成方法 | |
CN1895302A (zh) | 一种具有抗肿瘤作用的“猕猴桃素”及其制备方法和应用 | |
CN1198639C (zh) | 新型免疫增强组合物 | |
CN1582160A (zh) | 用于治疗癌的新草本化学组合物 | |
CN1686317A (zh) | 具有神经保护作用的银杏总内酯组合物 | |
CN1165301C (zh) | 组合物在制备治疗癌症的药物中的用途 | |
CN1666982A (zh) | 来自牛樟芝菌丝体的新混合物和化合物及其用途 | |
CN1280279C (zh) | 双苯并异唑酮类化合物及其合成和应用 | |
CN1652805A (zh) | 一种用于治疗和改善支气管呼吸困难的草药组合物 | |
CN1251678C (zh) | 用于提升免疫力的医药组合物及茯苓萃取物 | |
CN101077873A (zh) | 新的neo-克罗烷型二萜化合物及其应用 | |
CN1566136A (zh) | 白头翁总皂苷及提取方法,以及医药用途和药物制剂 | |
CN100339377C (zh) | 喜树碱衍生物及其制备 | |
CN1594341A (zh) | 人参皂苷次级苷compound K的脂肪酸酯类化合物及制备方法 | |
CN1086815A (zh) | 2-(1-羟乙基)-5-羟基萘并[2,3-b]呋喃-4,9-二酮和含该化合物的抗肿瘤剂 | |
CN1566061A (zh) | 一种新的天然药物有效部位-尾叶香茶菜总二萜 | |
CN1532198A (zh) | 季白屈菜碱衍生物 | |
CN1565438A (zh) | 5-羟甲基糠醛类用于制备神经系统用药的用途 | |
CN1021908C (zh) | 新的二胺衍生物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: CONNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH; AP Free format text: FORMER OWNER: CONNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH Effective date: 20051230 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20051230 Address after: India New Delhi Applicant after: Council of Scientific & Industrial Research Co-applicant after: A Liya Wei Diya Sara Co. Address before: India New Delhi Applicant before: Council of Scientific & Industrial Research |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081224 Termination date: 20141205 |
|
EXPY | Termination of patent right or utility model |